Alcoholic liver disease diagnosis is suggested by an established history of habitual alcohol intake of sufficient length and intensity.
Signs of alcohol abuse and hepatic injury include malnutrition and muscle wasting, cutaneous telangiectasia, palmar erythema, finger clubbing, Dupuytren's contracture, peripheral neuropathy, parotid gland enlargement and signs of gynecomastia and hypogonadism may also be present. Patient may also be asymptomatic.
The combination therapy of cilofexor (CILO) and firsocostat (FIR) missed the primary endpoint but achieved improvements in other secondary parameters including fibrosis markers, disease activity, and liver function in patients with fibrosis due to NASH*, according to the ATLAS trial presented at digital ILC 2020.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Gastroenterology - Malaysia digital copy today!
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.